Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2)

Anticancer Research

Volumn 20, Issue 6 A, 2000, Pages 4081-4086

  Yamamoto, M ^a   Fukushima, T ^a   Ueno, Y ^a   Hayashi, S ^a   Kimura, H ^a   Soma, G I ^a   Tomonaga, M ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EMAPII; Glioblastoma; Recombinant mutant tumor necrosis factor alpha (TNF SAM2)

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; POLYPEPTIDE; RANIMUSTINE; RECOMBINANT MUTANT HUMAN TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; NAUSEA; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; VOMITING;

AGED; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033635636     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Procarbazine, CCNU, and vincristine (PCV) combination chemotherapy for brain tumors
2. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
3. Recombinant beta interferon in patients with recurrent malignant gliomas
4. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma
5. A phase I clinical trial of recombinant human tumor necrosis factor
6. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
7. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience
8. Phase I study of recombinant human tumor necrosis factor
9. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas
10. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha
11. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNFα in vivo
12. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2)
13. Correlation of the expression of nuclear factor-κB, tumor necrosis factor receptor type 1 (TNFR1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2)
14. Tumor necrosis factor (TNF)
15. Tumor necrosis factor
16. Cell cycle-dependent tumor necrosis factor apoptosis
17. Clinical effect of intraarterial tumor necrosis factor-alpha for malignant glioma
18. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas
19. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin
20. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-α is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII)
21. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms
22. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II
23. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor
24. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-α, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model
25. Reporting results of cancer treatment
26. Increased expression of low density lipoprotein receptor-related protein/α2-macroglobulin receptor in human malignant astrocytomas
27. Cloning and expression of human endothelial-monocyte-activating polypeptide 2 (EMAP-2) and identification of its putative precursor
28. Suppression of TNF-alpha-induced apoptosis by NF-kappaB
29. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
30. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
31. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes
32. Macroscopic and microscopic early effects of tumor necrosis factor on murine Meth A sarcoma, and relation to curative activity
33. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells
34. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus
35. Effect of recombinant tumor necrosis factor-alpha on three-dimensional growth, morphology, and invasiveness of human glioblastoma cells in vitro
36. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNF alpha)
37. Evidence for the involvement of endothelial cell integrin alpha Vbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma
38. Tumor suppression and sensitization to tumor necrosis factor α-induced apoptosis by a interferon-inducible protein, p202, in breast cancer cells